DE3222072C2 - Humane T-Zell-Linien und Verfahren zu ihrer Herstellung - Google Patents
Humane T-Zell-Linien und Verfahren zu ihrer HerstellungInfo
- Publication number
- DE3222072C2 DE3222072C2 DE3222072A DE3222072A DE3222072C2 DE 3222072 C2 DE3222072 C2 DE 3222072C2 DE 3222072 A DE3222072 A DE 3222072A DE 3222072 A DE3222072 A DE 3222072A DE 3222072 C2 DE3222072 C2 DE 3222072C2
- Authority
- DE
- Germany
- Prior art keywords
- cells
- human
- cell
- line
- factors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 title claims description 7
- 230000008569 process Effects 0.000 title claims 3
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 210000004754 hybrid cell Anatomy 0.000 claims abstract description 6
- 102000008072 Lymphokines Human genes 0.000 claims abstract 3
- 108010074338 Lymphokines Proteins 0.000 claims abstract 3
- 210000004027 cell Anatomy 0.000 claims description 58
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 claims description 22
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 claims description 12
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 claims description 12
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 9
- 229960005508 8-azaguanine Drugs 0.000 claims description 6
- 230000002950 deficient Effects 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 230000012010 growth Effects 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 230000002380 cytological effect Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 238000009396 hybridization Methods 0.000 claims 4
- 210000004408 hybridoma Anatomy 0.000 claims 4
- 230000004957 immunoregulator effect Effects 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 230000004071 biological effect Effects 0.000 claims 2
- 230000007910 cell fusion Effects 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 108700031361 Brachyury Proteins 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000003698 anagen phase Effects 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000008859 change Effects 0.000 claims 1
- 230000007012 clinical effect Effects 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 230000016784 immunoglobulin production Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 229940047122 interleukins Drugs 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 210000001541 thymus gland Anatomy 0.000 claims 1
- 239000002609 medium Substances 0.000 description 16
- 239000012980 RPMI-1640 medium Substances 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 108010062580 Concanavalin A Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010047620 Phytohemagglutinins Proteins 0.000 description 3
- 108010033737 Pokeweed Mitogens Proteins 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 230000001885 phytohemagglutinin Effects 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010089814 Plant Lectins Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000000061 acid fraction Substances 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000007193 modulation by symbiont of host erythrocyte aggregation Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000003726 plant lectin Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/948—Microorganisms using viruses or cell lines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56091265A JPS57206383A (en) | 1981-06-12 | 1981-06-12 | Human t cellular line |
| JP56122815A JPS5823785A (ja) | 1981-08-04 | 1981-08-04 | ヒトｔ細胞ライン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3222072A1 DE3222072A1 (de) | 1983-04-07 |
| DE3222072C2 true DE3222072C2 (de) | 1986-08-14 |
Family
ID=26432716
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3222072A Expired DE3222072C2 (de) | 1981-06-12 | 1982-06-11 | Humane T-Zell-Linien und Verfahren zu ihrer Herstellung |
| DE3249567A Expired DE3249567C2 (de) | 1981-06-12 | 1982-06-11 | Hybridzell-Linie, Verfahren zu ihrer Herstellung und ihre Verwendung |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3249567A Expired DE3249567C2 (de) | 1981-06-12 | 1982-06-11 | Hybridzell-Linie, Verfahren zu ihrer Herstellung und ihre Verwendung |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US4544632A (en:Method) |
| AT (2) | AT387235B (en:Method) |
| AU (1) | AU555913B2 (en:Method) |
| CA (1) | CA1189805A (en:Method) |
| CH (1) | CH663795A5 (en:Method) |
| DE (2) | DE3222072C2 (en:Method) |
| DK (1) | DK255882A (en:Method) |
| ES (1) | ES513027A0 (en:Method) |
| FI (1) | FI76118C (en:Method) |
| FR (1) | FR2507620A1 (en:Method) |
| GB (1) | GB2102832B (en:Method) |
| IT (1) | IT1164454B (en:Method) |
| NL (1) | NL8202379A (en:Method) |
| NO (1) | NO162669C (en:Method) |
| NZ (1) | NZ200849A (en:Method) |
| SE (2) | SE460852B (en:Method) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3379055D1 (en) * | 1982-06-09 | 1989-03-02 | Asahi Chemical Ind | Method for producing human antibody |
| NZ206699A (en) * | 1982-12-30 | 1989-08-29 | Bio Response Inc | Process for the production of serum independent cell lines |
| JPS59169489A (ja) * | 1983-03-15 | 1984-09-25 | Otsuka Pharmaceut Co Ltd | ヒト培養株化細胞 |
| JPS59169492A (ja) * | 1983-03-15 | 1984-09-25 | Asahi Chem Ind Co Ltd | ヒト融合細胞からの生理活性物質の産生方法 |
| US4728614A (en) * | 1983-05-18 | 1988-03-01 | Ortho Pharmaceutical | Mutant human T cell line producing immunosuppressive factor and method for obtaining such mutants |
| US4843004A (en) * | 1984-05-11 | 1989-06-27 | Sloan-Kettering Institute For Cancer Research | Method for the production of human T-T cell hybrids and production suppressor factor by human T-T cell hybrids |
| US4665032A (en) * | 1984-06-28 | 1987-05-12 | Cornell Research Foundation, Inc. | Human T cell hybridomas which produce immunosuppressive factors |
| JP2529321B2 (ja) * | 1986-04-28 | 1996-08-28 | エンドトロニックス インコーポレーテッド | 白血球を培養する方法 |
| NO162160C (no) * | 1987-01-09 | 1989-11-15 | Medi Cult As | Serumfritt vekstmedium, samt anvendelse derav. |
| US5112735A (en) * | 1987-06-22 | 1992-05-12 | University Of Vermont | Detection of lymphocyte amplification |
| US6113903A (en) * | 1989-03-21 | 2000-09-05 | The Immune Response Corporation | Peptides and methods against diabetes |
| US5482837A (en) * | 1994-01-14 | 1996-01-09 | University Of Vermont | Methods of identifying lymphocytes with mutator phenotypes |
| US5827642A (en) * | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| ATE476496T1 (de) | 1996-03-04 | 2010-08-15 | Calyx Bio Ventures Inc | Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT292366B (de) * | 1968-08-28 | 1971-08-25 | Johann Sackl | Schweinezuchtstall |
| JPS57502090A (en:Method) * | 1980-07-18 | 1982-11-25 | ||
| US4451570A (en) * | 1981-03-26 | 1984-05-29 | The Regents Of The University Of California | Immunoglobulin-secreting human hybridomas from a cultured human lymphoblastoid cell line |
| US4401756A (en) * | 1981-04-14 | 1983-08-30 | Immunex Corporation | Process for preparing human interleukin 2 |
| US4407945A (en) * | 1981-04-29 | 1983-10-04 | Immunex Corporation | Constitutive production of interleukin 2 by a T cell hybridoma |
| US4434230A (en) * | 1981-08-12 | 1984-02-28 | Research Corporation | Human nonsecretory plasmacytoid cell line |
-
1982
- 1982-06-02 US US06/384,427 patent/US4544632A/en not_active Expired - Fee Related
- 1982-06-03 NZ NZ200849A patent/NZ200849A/en unknown
- 1982-06-04 AU AU84474/82A patent/AU555913B2/en not_active Ceased
- 1982-06-07 GB GB08216487A patent/GB2102832B/en not_active Expired
- 1982-06-07 DK DK255882A patent/DK255882A/da unknown
- 1982-06-08 CA CA000404685A patent/CA1189805A/en not_active Expired
- 1982-06-10 SE SE8203623A patent/SE460852B/sv not_active IP Right Cessation
- 1982-06-10 CH CH3602/82A patent/CH663795A5/de not_active IP Right Cessation
- 1982-06-10 SE SE8203623D patent/SE8203623L/xx not_active Application Discontinuation
- 1982-06-10 IT IT05179/82A patent/IT1164454B/it active
- 1982-06-10 FR FR8210121A patent/FR2507620A1/fr active Granted
- 1982-06-11 ES ES513027A patent/ES513027A0/es active Granted
- 1982-06-11 NL NL8202379A patent/NL8202379A/nl unknown
- 1982-06-11 NO NO821949A patent/NO162669C/no unknown
- 1982-06-11 DE DE3222072A patent/DE3222072C2/de not_active Expired
- 1982-06-11 DE DE3249567A patent/DE3249567C2/de not_active Expired
- 1982-06-11 FI FI822103A patent/FI76118C/fi not_active IP Right Cessation
- 1982-06-14 AT AT0230482A patent/AT387235B/de not_active IP Right Cessation
-
1983
- 1983-08-04 AT AT0281883A patent/AT377415B/de not_active IP Right Cessation
Non-Patent Citations (1)
| Title |
|---|
| NICHTS-ERMITTELT |
Also Published As
| Publication number | Publication date |
|---|---|
| ES8305039A1 (es) | 1983-04-01 |
| AU555913B2 (en) | 1986-10-16 |
| US4544632A (en) | 1985-10-01 |
| SE460852B (sv) | 1989-11-27 |
| DE3249567C2 (de) | 1986-10-02 |
| AU8447482A (en) | 1982-12-16 |
| AT377415B (de) | 1985-03-25 |
| FI822103A0 (fi) | 1982-06-11 |
| GB2102832A (en) | 1983-02-09 |
| NL8202379A (nl) | 1983-01-03 |
| ATA281883A (de) | 1984-08-15 |
| NO162669B (no) | 1989-10-23 |
| ATA230482A (de) | 1988-05-15 |
| CA1189805A (en) | 1985-07-02 |
| CH663795A5 (de) | 1988-01-15 |
| GB2102832B (en) | 1985-03-20 |
| NO821949L (no) | 1982-12-13 |
| SE8203623L (sv) | 1982-12-13 |
| ES513027A0 (es) | 1983-04-01 |
| NO162669C (no) | 1990-01-31 |
| DE3222072A1 (de) | 1983-04-07 |
| IT8205179A0 (it) | 1982-06-10 |
| FR2507620A1 (fr) | 1982-12-17 |
| DK255882A (da) | 1982-12-13 |
| FI76118C (fi) | 1988-09-09 |
| FR2507620B1 (en:Method) | 1984-10-19 |
| FI76118B (fi) | 1988-05-31 |
| AT387235B (de) | 1988-12-27 |
| IT1164454B (it) | 1987-04-08 |
| NZ200849A (en) | 1985-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3222072C2 (de) | Humane T-Zell-Linien und Verfahren zu ihrer Herstellung | |
| DE69834527T2 (de) | Verfahren zur Geschlechtsbestimmung von Säuger-Nachkommenschaft | |
| DE68927277T2 (de) | CD40 kodierende DNA | |
| EP0093436B1 (de) | Verfahren zur Herstellung permanenter tierischer und humaner Zellinien und deren Verwendung | |
| DE3235924C2 (en:Method) | ||
| DE3144181A1 (de) | "human-myelomazell-linie und verfahren zur herstellung einer hybridzell-linie" | |
| DE2314076A1 (de) | Verfahren zur herstellung von karzinoembryonischem antigen | |
| CH683526A5 (de) | Zellinie für die Herstellung von Antikörper bildenden Hybridomen, Verfahren zur Herstellung einer menschlichen Zellinie und Antikörper produzierendes Hybridom. | |
| DE69806427T2 (de) | Verfahren zum Erfassen von Hämatopoetischen Vorläuferzellen | |
| DE69329340T2 (de) | Aufbewahren von stammzellen | |
| DE69226350T2 (de) | Zellkulturverfahren und medium für das wachstum adhärenter tierzellen | |
| DE69434637T2 (de) | Hepatoblasten und verfahren zu ihrer isolierung | |
| DE3650635T2 (de) | Monoklonale Antikörper | |
| SHAH | Sporogony of the oocysts of Isospora felis Wenyon, 1923 from the cat | |
| DE2726988A1 (de) | Verfahren zur herstellung eines reagens zur bestimmung von menschlichen leukozyten-antigenen und seine anwendung | |
| DE60318271T2 (de) | Antikörper gegen allgegenwärtige mitochondriale Kreatinkinase und dessen Verwendung | |
| Tanaka et al. | Studies on microspore development in liliaceous plants II. The behavior of explanted microspores of the lily, Lilium longiflorum | |
| DE68925973T2 (de) | Zellenaussortierungstechnik und ihre anwendungen | |
| DE3239863A1 (de) | Verfahren zur herstellung von subkultivierbaren lymphokin-bildenden human-t-zellenhybridomas | |
| EP0197489A2 (de) | Hypoxanthin-guanin-phosphoribosyltransferase-negative Mutante einer histiozytischen permanenten humanen Zellinie | |
| Steward et al. | The labeling of cultured cells of Acer with [14C] proline and its significance | |
| DE19708877C1 (de) | Antikörper 97A6 | |
| DE69424153T2 (de) | Methode zur verbesserten herstellung einer produzierende zellinie durch verwendung eines fusionsprotokolls | |
| DE3627326A1 (de) | Immortalisierung durch dns-uebertragung | |
| DE69211539T2 (de) | Zellzucht von permanenten menschlichen Promyelocytezellinien, und deren Anwendung zum Screening von Molekulen für Behandlung von Leukemia. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8172 | Supplementary division/partition in: |
Ref country code: DE Ref document number: 3249567 Format of ref document f/p: P |
|
| Q171 | Divided out to: |
Ref country code: DE Ref document number: 3249567 |
|
| D2 | Grant after examination | ||
| AH | Division in |
Ref country code: DE Ref document number: 3249567 Format of ref document f/p: P |
|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |